Hence, cGAS-STING inhibition has the potential to decrease obesity-associated inflammation, type 2 diabetes mellitus (T2DM), NASH/NAFLD, defective wound healing, and angiogenesis. This evidence concerns the gene CGAS and obesity due to melanocortin 4 receptor deficiency.